Q2 2026

Filed Aug 14, 2026 · 10-Q · 45 days after period end · 0001104659-26-097188

Q2 2026 · 10-Q

Revenue

$807.00K

+516.0% vs Q2 2025

Net Income

-$9.22M

N/M vs Q2 2025

EPS Diluted

-$0.01

N/M vs Q2 2025

Operating Income-$11,605,000N/M

Operating Cash Flow

Same quarter

Metric	Q2 2026	Q2 2025	Q2 2024	Q2 2023
Revenue	$807.00K	$131.00K	$510.00K	$201.00K
Net Income	-$9.22M	-$15.38M	-$17.87M	-$14.45M
EPS Diluted	-$0.01	-$0.01	-$0.02	-$0.01

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Northwest Biotherapeutics Inc · CIK 1072379 · Engraved from SEC EDGAR